Numinus Wellness (DB:LR23) - Aandelenkoers, Nieuws & Analyse

LR23 Overzicht aandelen

Numinus Wellness Inc. levert producten en diensten voor psychedelische psychotherapie in Canada en de Verenigde Staten.

LR23 fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 60.27% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( €11M )

Heeft minder dan 1 jaar cash runway

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Aandeelhouders zijn het afgelopen jaar verwaterd

Numinus Wellness Inc. Concurrenten

MPH Health Care

DB:93M1

€101.0m

Biofrontera

XTRA:B8FK

€17.0m

SynBiotic

DUSE:SBX

€29.9m

Redx Pharma

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Numinus Wellness
Historische aandelenkoersen
Huidige aandelenkoers	CA$0.021
52 Week Hoogtepunt	CA$0.13
52 Week Laag	CA$0.015
Bèta	1.54
11 maand verandering	17.05%
3 maanden verandering	-21.67%
1 Jaar Verandering	-74.75%
33 jaar verandering	-95.84%
5 jaar verandering	n/a
Verandering sinds IPO	-93.69%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	LR23	DE Pharmaceuticals	DE Markt
7D	37.3%	-2.5%	-0.2%
1Y	-74.8%	-14.4%	12.9%

Rendement versus industrie: LR23 presteerde slechter dan de German Pharmaceuticals -sector, die het afgelopen jaar een rendement van -14.4 % opleverde.

Rendement versus markt: LR23 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 12.9 % opleverde.

Prijsvolatiliteit

Is LR23's price volatile compared to industry and market?
LR23 volatility
LR23 Average Weekly Movement	25.2%
Pharmaceuticals Industry Average Movement	7.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van LR23 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 25% ) van LR23 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1964	n/a	Payton Nyquvest	www.numinus.com

Numinus Wellness Inc. levert producten en diensten voor psychedelische psychotherapie in Canada en de Verenigde Staten. Het bedrijf opereert via de segmenten Clinical Research Operations, Canadian Clinic Network en U.S Clinic Network. Het segment Clinical Research Operations biedt managementdiensten voor klinisch onderzoek aan academische instellingen en biotechnologiebedrijven.

Numinus Wellness Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Numinus Wellness zich tot de beurswaarde?
LR23 fundamentele statistieken
Marktkapitalisatie	€7.56m
Inkomsten(TTM)	-€17.10m
Inkomsten(TTM)	€15.07m

0.5x

P/S-verhouding

-0.4x

Koers/Winstverhouding

Is LR23 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
LR23 resultatenrekening (TTM)
Inkomsten	CA$22.48m
Kosten van inkomsten	CA$15.68m
Brutowinst	CA$6.80m
Overige uitgaven	CA$32.31m
Inkomsten	-CA$25.51m

Laatst gerapporteerde inkomsten

May 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.079
Brutomarge	30.27%
Nettowinstmarge	-113.45%
Schuld/Eigen Vermogen Verhouding	35.4%

Hoe presteerde LR23 op de lange termijn?

Bekijk historische prestaties en vergelijking

LR23 Overzicht aandelen

Beloningen

Risicoanalyse

Numinus Wellness Inc. Concurrenten

DB:93M1

€101.0m

XTRA:B8FK

€17.0m

DUSE:SBX

€29.9m

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Forecast to breakeven in 2026

Third quarter 2024 earnings released: CA$0.019 loss per share (vs CA$0.028 loss in 3Q 2023)

Numinus Wellness Inc. to Report Q3, 2024 Results on Jul 11, 2024

Numinus Wellness Inc. Appoints Jaime Gerber to Numinus Intelligence Board

MedBright AI Investments Inc. (CNSX:MBAI) executed a letter of intent to acquire MedBright AI Investments Inc. (TSX:NUMI) for CAD 16.2 million in a reverse merger transaction.

Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD

Recent updates

Forecast to breakeven in 2026

Third quarter 2024 earnings released: CA$0.019 loss per share (vs CA$0.028 loss in 3Q 2023)

Numinus Wellness Inc. to Report Q3, 2024 Results on Jul 11, 2024

Numinus Wellness Inc. Appoints Jaime Gerber to Numinus Intelligence Board

MedBright AI Investments Inc. (CNSX:MBAI) executed a letter of intent to acquire MedBright AI Investments Inc. (TSX:NUMI) for CAD 16.2 million in a reverse merger transaction.

Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD

Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy

Second quarter 2024 earnings released: CA$0.023 loss per share (vs CA$0.028 loss in 2Q 2023)

Numinus Wellness Inc. to Report Q2, 2024 Results on Apr 15, 2024

Numinus Wellness Inc. Submits Clinical Trial Application

Numinus Wellness Inc., Annual General Meeting, May 21, 2024

Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 6 million.

First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.024 loss in 1Q 2023)

Numinus Wellness Inc., Annual General Meeting, Feb 26, 2024

Insufficient new directors

Full year 2023 earnings released: CA$0.12 loss per share (vs CA$0.17 loss in FY 2022)

Numinus Wellness Inc. to Report Q4, 2023 Results on Nov 29, 2023

Numinus Wellness Inc. Introduces Its Innovative and Comprehensive Psychedelic Program for Individuals Surging from Mental Distress Associated with Chronic and Serious Illness Through Cedar Clinical Research

Forecast to breakeven in 2026

Third quarter 2023 earnings released: CA$0.028 loss per share (vs CA$0.033 loss in 3Q 2022)

Numinus Wellness Inc. to Report Q3, 2023 Results on Jul 17, 2023

Numinus Wellness Inc. Appoints Nikhil Handa as Chief Financial Officer, Effective from June 15, 2023

Numinus Wellness Inc. Announces Cedar Clinical Research

Numinus Wellness Inc. Announces to Research COMP360 Psilocybin Therapy in Treatment-Resistant Depression as Part of Large Phase 3 Study

Numinus Wellness Inc Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

Second quarter 2023 earnings released: CA$0.028 loss per share (vs CA$0.038 loss in 2Q 2022)

Numinus Wellness Inc. Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training Using Psilocybe Cubensis Tea

First quarter 2023 earnings released: CA$0.024 loss per share (vs CA$0.026 loss in 1Q 2022)

Numinus Wellness Inc. to Report Q1, 2023 Results on Jan 16, 2023

Numinus Wellness Inc., Annual General Meeting, Feb 15, 2023

Numinus Wellness Inc. Submits Clinical Trial Application to Health Canada for Experiential Psilocybin Assisted Therapy Training Research

Full year 2022 earnings released: CA$0.21 loss per share (vs CA$0.11 loss in FY 2021)

Numinus Wellness Inc. Reports Impairment of Good Will for the Fourth Quarter Ended August 31, 2022

High number of new and inexperienced directors

Numinus Wellness Inc. Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

Numinus Develops Mushroom Tea for Use in Psychedelic Research

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Numinus Wellness Inc. to Report Q4, 2022 Results on Nov 29, 2022

Third quarter 2022 earnings released: CA$0.033 loss per share (vs CA$0.025 loss in 3Q 2021)

Numinus Wellness Inc. to Report Q3, 2022 Results on Jul 14, 2022

Numinus Wellness Inc. Announces Launch of Pilots Mental Health Program for Corporate Clients in Utah

Numinus Wellness Inc. Announces That Its Subsidiary Numinus Bioscience Inc Applies for International Patent Filing of Psychedelics Production Process

Numinus Wellness Inc. (TSX:NUMI) completed the acquisition of Novamind Inc. (OTCPK:NVMD.F).

Numinus Wellness Inc. Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment

Numinus Announces the Music as Medicine Event Series

High number of new and inexperienced directors

Second quarter 2022 earnings released: CA$0.038 loss per share (vs CA$0.028 loss in 2Q 2021)

Numinus Wellness Inc. (TSX:NUMI) entered into a definitive agreement to acquire Novamind Inc. (OTCPK:NVMD.F) for CAD 21.6 million.

Numinus Wellness Inc. to Report Q2, 2022 Results on Apr 14, 2022

Numinus Wellness Inc. Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

Numinus Wellness Inc. Appoints New Bioscience Advisors to Advance IP Development

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Psilocybin and MDMA Get the Green Light for Medical Use in Canada

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

Numinus Wellness Inc.(TSXV:NUMI) dropped from S&P/TSX Venture Composite Index

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Numinus Wellness Inc. (TSXV:NUMI) completed the acquisition of Neurology Centre of Toronto.

Third quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.035 loss in 3Q 2020)

Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for Post-Traumatic Stress Disorder